Dyax Corp. Company Profile (NASDAQ:DYAX)

About Dyax Corp.

Dyax Corp. logoDyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: DYAX
  • CUSIP: 26746E10
Key Metrics:
  • Previous Close: $38.41
  • 50 Day Moving Average: $37.73
  • 200 Day Moving Average: $29.05
  • 52-Week Range: $14.06 - $38.56
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -274.36
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:
Companies Related to Dyax Corp.:

Analyst Ratings

Consensus Ratings for Dyax Corp. (NASDAQ:DYAX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Dyax Corp. (NASDAQ:DYAX)
Show:
DateFirmActionRatingPrice TargetDetails
12/7/2015Royal Bank Of CanadaReiterated RatingBuyView Rating Details
11/9/2015Leerink SwannDowngradeOutperform -> Market Perform$37.00View Rating Details
11/5/2015Needham & Company LLCDowngradeBuy -> HoldView Rating Details
11/2/2015Jefferies Group LLCDowngradeBuy -> Hold$37.00View Rating Details
11/2/2015WedbushDowngradeOutperform -> NeutralView Rating Details
5/11/2015Oppenheimer Holdings, Inc.DowngradeOutperform -> Market Perform$26.00View Rating Details
4/1/2015Bank of America CorpBoost Price TargetBuy$16.00 -> $30.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Dyax Corp. (NASDAQ:DYAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2016        
10/28/2015Q315($0.08)($0.08)$24.96 million$24.70 millionViewN/AView Earnings Details
7/29/2015Q215($0.04)($0.06)$23.40 million$264.00 millionViewListenView Earnings Details
4/29/2015Q115($0.05)($0.05)$21.79 million$20.40 millionViewN/AView Earnings Details
2/24/2015Q414($0.04)($0.02)$19.90 million$26.00 millionViewN/AView Earnings Details
10/28/2014Q314($0.06)($0.01)$15.70 million$22.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.05)($0.02)$14.13 million$19.59 millionViewN/AView Earnings Details
4/30/2014($0.05)($0.05)ViewN/AView Earnings Details
2/28/2014Q413($0.04)($0.02)$15.84 million$16.90 millionViewN/AView Earnings Details
10/22/2013Q313($0.05)($0.06)$14.80 million$13.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dyax Corp. (NASDAQ:DYAX)
Current Year EPS Consensus Estimate: $-0.26 EPS
Next Year EPS Consensus Estimate: $-0.14 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.04)($0.04)($0.04)
Q2 20161($0.04)($0.04)($0.04)
Q3 20161($0.03)($0.03)($0.03)
Q4 20162($0.01)$0.01$0.00
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dyax Corp. (NASDAQ:DYAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Dyax Corp. (NASDAQ:DYAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/10/2015Thomas L KempnerDirectorSell6,000$22.47$134,820.00View SEC Filing  
8/28/2015Thomas L KempnerDirectorSell17,947$23.83$427,677.01View SEC Filing  
8/18/2015Thomas L KempnerDirectorSell18,035$23.83$429,774.05View SEC Filing  
8/13/2015Thomas L KempnerDirectorSell4,848$23.81$115,430.88View SEC Filing  
7/20/2015Henry E BlairDirectorSell50,000$27.05$1,352,500.00View SEC Filing  
6/8/2015David J MclachlanDirectorSell75,000$25.63$1,922,250.00View SEC Filing  
3/6/2015Andrew D AsheEVPSell2,400$15.50$37,200.00View SEC Filing  
3/5/2015Burt A AdelmanCMOSell9,375$15.66$146,812.50View SEC Filing  
3/5/2015George V MigauskyCFOSell5,000$15.86$79,300.00View SEC Filing  
3/5/2015Gustav ChristensenCEOSell6,250$15.86$99,125.00View SEC Filing  
2/26/2015Andrew D AsheEVPSell1,500$15.34$23,010.00View SEC Filing  
1/2/2015Burt A AdelmanCMOSell75,000$14.05$1,053,750.00View SEC Filing  
12/5/2014Thomas L KempnerDirectorSell14,764$13.79$203,595.56View SEC Filing  
11/21/2014Thomas L KempnerDirectorSell100,000$13.20$1,320,000.00View SEC Filing  
9/12/2014Thomas L KempnerDirectorSell12,400$11.00$136,400.00View SEC Filing  
8/26/2014Thomas L KempnerDirectorSell37,000$10.39$384,430.00View SEC Filing  
8/19/2014Thomas L KempnerDirectorSell113,755$9.67$1,100,010.85View SEC Filing  
8/7/2014Thomas L KempnerDirectorSell33,190$9.25$307,007.50View SEC Filing  
6/13/2014George V MigauskyCFOSell16,000$8.26$132,160.00View SEC Filing  
3/5/2014Henry BlairDirectorSell150,000$10.46$1,569,000.00View SEC Filing  
3/3/2014Andrew AsheEVPSell30,000$10.00$300,000.00View SEC Filing  
3/3/2014Burt AdelmanCMOSell55,000$9.68$532,400.00View SEC Filing  
2/26/2014Andrew AsheVPSell2,723$10.10$27,502.30View SEC Filing  
12/5/2013Thomas KempnerDirectorSell400,000$8.37$3,348,000.00View SEC Filing  
8/13/2013Andrew AsheVPSell32,500$4.30$139,750.00View SEC Filing  
5/16/2013Marc D KozinDirectorBuy22,971$2.46$56,508.66View SEC Filing  
2/25/2013George V MigauskyCFOSell4,275$3.28$14,022.00View SEC Filing  
2/25/2013Ivana MagovcevicCOOSell4,015$3.24$13,008.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Dyax Corp. (NASDAQ:DYAX)
DateHeadline
News IconNovel Kallikrein Inhibitor Promising for HAE Prophylaxis - MedPage Today (NASDAQ:DYAX)
www.medpagetoday.com - February 22 at 5:06 PM
prnewswire.com logoShire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in ... - PR Newswire (press release) (NASDAQ:DYAX)
www.prnewswire.com - February 18 at 9:39 AM
istreetwire.com logoWorth Watching Stocks: Rex Energy Corporation (REXX), RSP ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - February 16 at 3:37 PM
finance.yahoo.com logoShire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in ... - Yahoo Finance (NASDAQ:DYAX)
finance.yahoo.com - February 16 at 3:37 PM
4-traders.com logoShire : to Highlight Advancements in Rare Genetic Diseases (NASDAQ:DYAX)
www.4-traders.com - February 14 at 5:47 PM
live-pr.com logoDyax Corp. - Strategy, SWOT and Corporate Finance Report - New Study Released (NASDAQ:DYAX)
www.live-pr.com - February 14 at 5:47 PM
openpr.com logoGlobal Next-generation Antibody Therapeutics Market will Reach US$ 6,761.1 Million by 2022 (NASDAQ:DYAX)
www.openpr.com - February 13 at 8:32 AM
istreetwire.com logoStocks To Track: Merrimack Pharmaceuticals, Inc. (MACK), Mueller Water Products, Inc. (MWA), The Western Union ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - February 8 at 10:24 PM
4-traders.com logoShire : Responds to U.S. Federal Trade Commission Civil Action (NASDAQ:DYAX)
www.4-traders.com - February 7 at 6:02 PM
istreetwire.com logoThree Movers to Watch for: Heartland Express, Inc. (HTLD), The Chemours Company (CC), Merrimack ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - February 1 at 3:32 AM
News IconJennison Associates LLC Position in Shire Plc (SHPG) Trimmed by $34.49 Million as Share Price Rose - The Randolph Guide (NASDAQ:DYAX)
randolphguide.com - January 30 at 5:43 PM
istreetwire.com logoMomentum Stocks in Focus: Pitney Bowes Inc. (PBI), Merrimack ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - January 28 at 4:34 AM
News IconNext-generation Antibody Therapeutics Market is Estimated to be Valued at US$ 6,761.1 Million by 2022 (NASDAQ:DYAX)
www.medgadget.com - January 27 at 6:27 PM
marketwatch.com logoWho is the top fee payer to banks in Europe? (NASDAQ:DYAX)
www.marketwatch.com - January 27 at 6:27 PM
istreetwire.com logoWorth Watching Stocks: United Continental Holdings, Inc. (UAL), Staples, Inc. (SPLS), Merrimack Pharmaceuticals, Inc ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - January 25 at 11:02 PM
istreetwire.com logoStocks To Track: Keryx Biopharmaceuticals, Inc. (KERX), Parsley Energy, Inc. (PE), Merrimack Pharmaceuticals, Inc ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - January 25 at 11:02 PM
News IconEarnings in Full Force, Analysts Take Aim at Dyax Corp. (NASDAQ:DYAX) - Wall Street Beacon (NASDAQ:DYAX)
wsbeacon.com - January 25 at 11:02 PM
openpr.com logoRare Disease Treatment Market Expecting Worldwide Growth by 2024 – Persistence Market Research (NASDAQ:DYAX)
www.openpr.com - January 25 at 6:01 PM
istreetwire.com logoStocks In Queue: Valero Energy Corporation (VLO), Merrimack Pharmaceuticals, Inc. (MACK), Rice Energy Inc. (RICE) - iStreetWire (NASDAQ:DYAX)
istreetwire.com - January 22 at 4:47 PM
finance.yahoo.com logoTop 6 Vendors in the Global Myasthenia Gravis Drugs Market from 2017 to 2021: Technavio - Yahoo Finance (NASDAQ:DYAX)
finance.yahoo.com - January 22 at 4:47 PM
News IconDyax Corp Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:DYAX)
www.bioportfolio.com - January 20 at 6:04 PM
istreetwire.com logoInvestor's Watch List: Ocwen Financial Corporation (OCN), Merrimack Pharmaceuticals, Inc. (MACK), CBS Corporation ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - January 19 at 6:15 PM
istreetwire.com logoStocks Alert: Brookdale Senior Living Inc. (BKD), Merrimack Pharmaceuticals, Inc. (MACK), The Home Depot, Inc. (HD) - iStreetWire (NASDAQ:DYAX)
istreetwire.com - January 18 at 10:27 PM
openpr.com logoHereditary Angioedema (HAE) Market : Technological Breakthroughs, Value Chain And Stakeholder Analysis By 2024 (NASDAQ:DYAX)
www.openpr.com - January 18 at 5:16 PM
News IconWill The Needle Move For Dyax Corp. (NASDAQ:DYAX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:DYAX)
wsbeacon.com - January 17 at 5:41 PM
News IconCity Moves for 16 January 2017 | Who's switching jobs | City A.M. - City A.M. (NASDAQ:DYAX)
www.cityam.com - January 16 at 4:52 PM
istreetwire.com logoInvestor's Watch List: Forest City Realty Trust, Inc (FCE-A), Celgene ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - January 13 at 11:07 PM
News IconShort Interest Don't Lie: Could ARB CORPORATION LTD ORD ... - Baxley Report (NASDAQ:DYAX)
baxleyreport.com - January 13 at 11:07 PM
istreetwire.com logo3 Stocks to Watch For: Advanced Micro Devices, Inc. (AMD), EnteroMedics Inc. (ETRM), Merrimack Pharmaceuticals ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - January 12 at 3:28 AM
istreetwire.com logoInvestor's Watch List: Merrimack Pharmaceuticals, Inc. (MACK), eBay Inc. (EBAY), Hewlett Packard Enterprise ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - January 12 at 3:28 AM
News IconJetBlue Airways Corporation (JBLU) Rating Reiterate by the Imperial Capital (NASDAQ:DYAX)
myhealthbowl.com - January 10 at 5:49 PM
News IconActive Volume Stock: JetBlue Airways Corporation (NASDAQ:JBLU) (NASDAQ:DYAX)
thecelebritytruth.com - January 10 at 5:49 PM
News IconDyax Corp. Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:DYAX)
www.bioportfolio.com - January 8 at 6:06 AM
News IconHereditary Angioedema (HAE) Market :Advanced Technologies & Growth Opportunities In Global Industry By 2024 (NASDAQ:DYAX)
www.medgadget.com - January 7 at 5:45 PM
News IconNext-generation Antibody Therapeutics Market is Appraised to be Valued US$ 6,761.1 Million by 2022 (NASDAQ:DYAX)
satprnews.com - January 4 at 5:57 PM
istreetwire.com logoStock's Trend Analysis Report: Merrimack Pharmaceuticals, Inc. (MACK), Gramercy Property Trust, Inc. (GPT ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - December 31 at 4:53 PM
istreetwire.com logoMomentum Stocks in Focus: Achillion Pharmaceuticals, Inc. (ACHN), Merrimack Pharmaceuticals, Inc. (MACK), Ascena ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - December 29 at 3:44 PM
istreetwire.com logo3 Notable Runners: Merrimack Pharmaceuticals, Inc. (MACK ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - December 29 at 3:44 PM
News IconPropranolol Cheapest Prices, How to Buy Propranolol Online - 4966 orders completed today (NASDAQ:DYAX)
theeyeopener.com - December 28 at 11:49 AM
newsmaker.com.au logoRare Disease Treatment Market is Expected to Gain Popularity Across the Globe (NASDAQ:DYAX)
www.newsmaker.com.au - December 27 at 11:51 AM
istreetwire.com logoWorth Watching Stocks: Merrimack Pharmaceuticals, Inc. (MACK), Merck & Co., Inc. (MRK), Oracle Corporation (ORCL) - iStreetWire (NASDAQ:DYAX)
istreetwire.com - December 22 at 10:04 PM
smarteranalyst.com logoStock Update (NASDAQ:XOMA): Here's Why XOMA Shares Are ... - Smarter Analyst (NASDAQ:DYAX)
www.smarteranalyst.com - December 22 at 10:04 PM
streetinsider.com logoXOMA (XOMA) Sells Two Royalty Streams, Reduces Headcount and ... - StreetInsider.com (NASDAQ:DYAX)
www.streetinsider.com - December 21 at 10:40 PM
News IconFuture of Global Rare Disease Treatment Market: 2016 – 2024 (NASDAQ:DYAX)
www.medgadget.com - December 21 at 5:38 PM
streetinsider.com logoXOMA (XOMA) Sells Two Royalty Streams, Reduces Headcount and Names New CEO (NASDAQ:DYAX)
www.streetinsider.com - December 21 at 5:38 PM
News IconNext-generation Antibody Therapeutics Market to Surpass US$ 6,761.1 Million by 2022 (NASDAQ:DYAX)
www.mynewsdesk.com - December 21 at 5:38 PM
openpr.com logoMarket Study on Expected Growth for Rare Disease Treatment Market (NASDAQ:DYAX)
www.openpr.com - December 20 at 6:03 PM
sbwire.com logoFuture of Global Rare Disease Treatment Market: Report Forecast 2016 to 2024 (NASDAQ:DYAX)
www.sbwire.com - December 20 at 6:03 PM
openpr.com logoNext-generation Antibody Therapeutics Market is Expected to Expand US$ 6,761.1 Million by 2022 (NASDAQ:DYAX)
www.openpr.com - December 12 at 11:59 AM
News IconThe Humira Story. How D2E7 Became a Star. A Personal Narrative & Vintage Slide Show. BASF Pharma. Abbott Bioresearch Center (NASDAQ:DYAX)
docplayer.net - December 8 at 8:54 AM

Social

What is Dyax Corp.'s stock symbol?

Dyax Corp. trades on the NASDAQ under the ticker symbol "DYAX."

When will Dyax Corp. announce their earnings?

Dyax Corp. is scheduled to release their next quarterly earnings announcement on Monday, February, 22nd 2016.

How do I buy Dyax Corp. stock?

Shares of Dyax Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Dyax Corp. stock cost?

One share of Dyax Corp. stock can currently be purchased for approximately $38.41.

Dyax Corp. (NASDAQ:DYAX) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Dyax Corp. (NASDAQ:DYAX)

Earnings History Chart

Earnings by Quarter for Dyax Corp. (NASDAQ:DYAX)

Dividend History Chart

Dividend Payments by Quarter for Dyax Corp. (NASDAQ:DYAX)

Last Updated on 2/24/2017 by MarketBeat.com Staff